MedTrace Logo

Repurposing Tilmanocept for Cardiac Sarcoidosis

NCT07159074 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to see if Tc 99m Tilmanocept SPECT/CT imaging can be used to identify cardiac sarcoidosis.

Conditions

  • Cardiac Sarcoidosis

Interventions

DRUG

Tc 99m tilmanocept

150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.

DRUG

Tc 99m tilmanocept

150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through a SC route of injection. SPECT-CT imaging will then be performed.

Sponsors & Collaborators

  • Foundation for Sarcoidosis Research

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • Ravi Karra, MD · Duke Health

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2026-12-01
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159074 on ClinicalTrials.gov